The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging

Eugene Y. Chang, Xin Li, Michael Jerosch-Herold, Ryan A. Priest, Charles Enestvedt, Jingang Xu, Charles Jr Springer, Blair A. Jobe

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Although neoadjuvant chemoradiation eradicates esophageal adenocarcinoma in a substantial proportion of patients, conventional imaging techniques cannot accurately detect this response. Dynamic contrast-enhanced magnetic resonance imaging is an emerging approach that may be well suited to fill this role. This pilot study evaluates the ability of this method to discriminate adenocarcinoma from normal esophageal tissue. Patients with esophageal adenocarcinoma and control subjects underwent scanning. Patients treated with neoadjuvant therapy underwent pre- and postchemoradiation scans. Parameters were extracted for each pixel were K trans (equilibrium rate for transfer of contrast reagent across the vascular wall), v e (volume fraction of interstitial space), and τ i (mean intracellular water lifetime). Five esophageal adenocarcinoma patients and two tumor-free control subjects underwent scanning. The mean K trans value was 5.7 times greater in esophageal adenocarcinoma, and τ i is 2.0 times smaller, than in the control subjects. K trans decreased by 11.4-fold after chemoradiation. Parametric maps qualitatively demonstrate a difference in K trans. DCE MRI of the esophagus is feasible. K trans, a parameter that has demonstrated discriminative ability in other malignancies, also shows promise in differentiating esophageal adenocarcinoma from benign tissue. The determination of K trans represents an in vivo assay for endothelial permeability and thus may serve as a quantitative measure of response to induction chemoradiation.

Original languageEnglish (US)
Pages (from-to)166-175
Number of pages10
JournalJournal of Gastrointestinal Surgery
Volume12
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Adenocarcinoma
Magnetic Resonance Imaging
Neoadjuvant Therapy
Esophagus
Blood Vessels
Permeability
Neoplasms
Water

Keywords

  • Dynamic contrast-enhanced magnetic resonance imaging
  • Esophageal adenocarcinoma
  • Neoadjuvant chemoradiation

ASJC Scopus subject areas

  • Surgery

Cite this

The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. / Chang, Eugene Y.; Li, Xin; Jerosch-Herold, Michael; Priest, Ryan A.; Enestvedt, Charles; Xu, Jingang; Springer, Charles Jr; Jobe, Blair A.

In: Journal of Gastrointestinal Surgery, Vol. 12, No. 1, 01.2008, p. 166-175.

Research output: Contribution to journalArticle

Chang, Eugene Y. ; Li, Xin ; Jerosch-Herold, Michael ; Priest, Ryan A. ; Enestvedt, Charles ; Xu, Jingang ; Springer, Charles Jr ; Jobe, Blair A. / The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. In: Journal of Gastrointestinal Surgery. 2008 ; Vol. 12, No. 1. pp. 166-175.
@article{18f2c6927674411088cbebe8b2a45352,
title = "The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging",
abstract = "Although neoadjuvant chemoradiation eradicates esophageal adenocarcinoma in a substantial proportion of patients, conventional imaging techniques cannot accurately detect this response. Dynamic contrast-enhanced magnetic resonance imaging is an emerging approach that may be well suited to fill this role. This pilot study evaluates the ability of this method to discriminate adenocarcinoma from normal esophageal tissue. Patients with esophageal adenocarcinoma and control subjects underwent scanning. Patients treated with neoadjuvant therapy underwent pre- and postchemoradiation scans. Parameters were extracted for each pixel were K trans (equilibrium rate for transfer of contrast reagent across the vascular wall), v e (volume fraction of interstitial space), and τ i (mean intracellular water lifetime). Five esophageal adenocarcinoma patients and two tumor-free control subjects underwent scanning. The mean K trans value was 5.7 times greater in esophageal adenocarcinoma, and τ i is 2.0 times smaller, than in the control subjects. K trans decreased by 11.4-fold after chemoradiation. Parametric maps qualitatively demonstrate a difference in K trans. DCE MRI of the esophagus is feasible. K trans, a parameter that has demonstrated discriminative ability in other malignancies, also shows promise in differentiating esophageal adenocarcinoma from benign tissue. The determination of K trans represents an in vivo assay for endothelial permeability and thus may serve as a quantitative measure of response to induction chemoradiation.",
keywords = "Dynamic contrast-enhanced magnetic resonance imaging, Esophageal adenocarcinoma, Neoadjuvant chemoradiation",
author = "Chang, {Eugene Y.} and Xin Li and Michael Jerosch-Herold and Priest, {Ryan A.} and Charles Enestvedt and Jingang Xu and Springer, {Charles Jr} and Jobe, {Blair A.}",
year = "2008",
month = "1",
doi = "10.1007/s11605-007-0253-5",
language = "English (US)",
volume = "12",
pages = "166--175",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging

AU - Chang, Eugene Y.

AU - Li, Xin

AU - Jerosch-Herold, Michael

AU - Priest, Ryan A.

AU - Enestvedt, Charles

AU - Xu, Jingang

AU - Springer, Charles Jr

AU - Jobe, Blair A.

PY - 2008/1

Y1 - 2008/1

N2 - Although neoadjuvant chemoradiation eradicates esophageal adenocarcinoma in a substantial proportion of patients, conventional imaging techniques cannot accurately detect this response. Dynamic contrast-enhanced magnetic resonance imaging is an emerging approach that may be well suited to fill this role. This pilot study evaluates the ability of this method to discriminate adenocarcinoma from normal esophageal tissue. Patients with esophageal adenocarcinoma and control subjects underwent scanning. Patients treated with neoadjuvant therapy underwent pre- and postchemoradiation scans. Parameters were extracted for each pixel were K trans (equilibrium rate for transfer of contrast reagent across the vascular wall), v e (volume fraction of interstitial space), and τ i (mean intracellular water lifetime). Five esophageal adenocarcinoma patients and two tumor-free control subjects underwent scanning. The mean K trans value was 5.7 times greater in esophageal adenocarcinoma, and τ i is 2.0 times smaller, than in the control subjects. K trans decreased by 11.4-fold after chemoradiation. Parametric maps qualitatively demonstrate a difference in K trans. DCE MRI of the esophagus is feasible. K trans, a parameter that has demonstrated discriminative ability in other malignancies, also shows promise in differentiating esophageal adenocarcinoma from benign tissue. The determination of K trans represents an in vivo assay for endothelial permeability and thus may serve as a quantitative measure of response to induction chemoradiation.

AB - Although neoadjuvant chemoradiation eradicates esophageal adenocarcinoma in a substantial proportion of patients, conventional imaging techniques cannot accurately detect this response. Dynamic contrast-enhanced magnetic resonance imaging is an emerging approach that may be well suited to fill this role. This pilot study evaluates the ability of this method to discriminate adenocarcinoma from normal esophageal tissue. Patients with esophageal adenocarcinoma and control subjects underwent scanning. Patients treated with neoadjuvant therapy underwent pre- and postchemoradiation scans. Parameters were extracted for each pixel were K trans (equilibrium rate for transfer of contrast reagent across the vascular wall), v e (volume fraction of interstitial space), and τ i (mean intracellular water lifetime). Five esophageal adenocarcinoma patients and two tumor-free control subjects underwent scanning. The mean K trans value was 5.7 times greater in esophageal adenocarcinoma, and τ i is 2.0 times smaller, than in the control subjects. K trans decreased by 11.4-fold after chemoradiation. Parametric maps qualitatively demonstrate a difference in K trans. DCE MRI of the esophagus is feasible. K trans, a parameter that has demonstrated discriminative ability in other malignancies, also shows promise in differentiating esophageal adenocarcinoma from benign tissue. The determination of K trans represents an in vivo assay for endothelial permeability and thus may serve as a quantitative measure of response to induction chemoradiation.

KW - Dynamic contrast-enhanced magnetic resonance imaging

KW - Esophageal adenocarcinoma

KW - Neoadjuvant chemoradiation

UR - http://www.scopus.com/inward/record.url?scp=38149009615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149009615&partnerID=8YFLogxK

U2 - 10.1007/s11605-007-0253-5

DO - 10.1007/s11605-007-0253-5

M3 - Article

VL - 12

SP - 166

EP - 175

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 1

ER -